<DOC>
	<DOCNO>NCT00124644</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cytarabine , daunorubicin , etoposide , work different way stop growth cancer cell , either kill cell stop dividing . Tipifarnib may stop growth cancer cell block enzymes need cell growth . Giving combination chemotherapy together tipifarnib may kill cancer cell . PURPOSE : This phase I trial study side effect best dose tipifarnib give together combination chemotherapy treat patient newly diagnose acute myeloid leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Tipifarnib Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose tipifarnib give combination induction therapy comprise cytarabine , daunorubicin , etoposide follow consolidation therapy comprise high-dose cytarabine patient newly diagnose high-risk acute myeloid leukemia . Secondary - Determine qualitative quantitative toxic effect regimen , term organ specificity , time course , predictability , reversibility , patient . - Determine rate complete remission patient treat regimen . - Determine remission duration , overall survival , relapse-free event-free survival patient treat regimen . - Determine pharmacokinetics regimen patient . - Correlate pharmacodynamic measurement level tumor necrosis factor-alpha clinical response patient treat regimen . OUTLINE : This dose-escalation study tipifarnib . - Induction therapy : Patients receive cytarabine IV continuously day 1-7 ; daunorubicin IV etoposide IV 2 hour day 5-7 ; oral tipifarnib twice daily day 5-12 . Patients undergo bone marrow biopsy day 17 OR day 17 24 ( day 17 bone marrow biopsy show suspicious disease ) . Patients achieve complete remission ( CR ) proceed consolidation therapy . Patients residual disease , define &gt; 5 % leukemic blast bone marrow ≥ 20 % cellularity , receive second course induction therapy comprise cytarabine IV continuously day 1-5 ; daunorubicin IV etoposide IV 2 hour day 4 5 ; oral tipifarnib twice daily day 4-9 . Patients achieve CR second course induction therapy proceed consolidation therapy . Patients achieve CR second course induction therapy remove study . Cohorts 3-6 patient receive escalate dos tipifarnib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . An additional 12 patient treated MTD . - Consolidation therapy : Patients receive high-dose cytarabine IV twice daily day 1 , 3 , 5 . Treatment repeat approximately every 6-8 week 4 course . After completion study treatment , patient follow every 3-6 month 5 year . PROJECTED ACCRUAL : A maximum 30 patient accrue study within 10-15 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm acute myeloid leukemia ( AML ) accord WHO classification system Highrisk disease Newly diagnose disease Patients secondary AML due prior chemotherapy different malignancy eligible No known inv ( 16 ) , ( 8 ; 21 ) , ( 15 ; 17 ) cytogenetic abnormality No acute promyelocytic leukemia No CNS leukemia PATIENT CHARACTERISTICS : Age 18 59 Performance status ECOG 02 Life expectancy More 6 month Hematopoietic Not specify Hepatic AST ALT ≤ 2.5 time upper limit normal Bilirubin normal Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular Ejection fraction &gt; 50 % echocardiogram MUGA No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Immunologic No known HIV positivity No history allergic reaction attribute compound similar chemical biological composition tipifarnib No allergy imidazole ( e.g. , clotrimazole , ketoconazole , miconazole , econazole ) No ongoing active infection Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled illness No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent epoetin alfa Chemotherapy See Disease Characteristics No prior chemotherapy AML myelodysplastic syndrome except hydroxyurea Endocrine therapy Not specify Radiotherapy No concurrent palliative radiotherapy Surgery Not specify Other More 30 day since prior investigational agent No concurrent investigational commercial agent therapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>